Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 2.73 0.00 (0.00%)
Day High: N/A
Day Low:  N/A
Volume:    N/A
4:00 PM ET
Aug 22, 2017

Delayed ~20 min., by eSignal.